期刊论文详细信息
BMC Public Health
Why the MDGs need good governance in pharmaceutical systems to promote global health
Natalia Ovtcharenko2  Tim Ken Mackey1  Jillian Clare Kohler2 
[1] Department of Anesthesiology, University of California San Diego School of Medicine, 200 West Arbor Drive, San Diego, CA 92103 USA;Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto M5S 3 M2, ON, Canada
关键词: Global institutions;    Access to medicines;    Pharmaceutical systems;    Health systems;    Corruption;    Good governance;   
Others  :  1161319
DOI  :  10.1186/1471-2458-14-63
 received in 2013-07-17, accepted in 2014-01-16,  发布年份 2014
PDF
【 摘 要 】

Background

Corruption in the health sector can hurt health outcomes. Improving good governance can in turn help prevent health-related corruption. We understand good governance as having the following characteristics: it is consensus-oriented, accountable, transparent, responsive, equitable and inclusive, effective and efficient, follows the rule of law, is participatory and should in theory be less vulnerable to corruption. By focusing on the pharmaceutical system, we explore some of the key lessons learned from existing initiatives in good governance. As the development community begins to identify post-2015 Millennium Development Goals targets, it is essential to evaluate programs in good governance in order to build on these results and establish sustainable strategies. This discussion on the pharmaceutical system illuminates why.

Discussion

Considering pharmaceutical governance initiatives such as those launched by the World Bank, World Health Organization, and the Global Fund, we argue that country ownership of good governance initiatives is essential but also any initiative must include the participation of impartial stakeholders. Understanding the political context of any initiative is also vital so that potential obstacles are identified and the design of any initiative is flexible enough to make adjustments in programming as needed. Finally, the inherent challenge which all initiatives face is adequately measuring outcomes from any effort. However in fairness, determining the precise relationship between good governance and health outcomes is rarely straightforward.

Summary

Challenges identified in pharmaceutical governance initiatives manifest in different forms depending on the nature and structure of the initiative, but their regular occurrence and impact on population-based health demonstrates growing importance of addressing pharmaceutical governance as a key component of the post-2015 Millennium Development Goals. Specifically, these challenges need to be acknowledged and responded to with global cooperation and innovation to establish localized and evidence-based metrics for good governance to promote global pharmaceutical safety.

【 授权许可】

   
2014 Kohler et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150413022811793.pdf 197KB PDF download
【 参考文献 】
  • [1]World Bank takes further step in anti-corruption fight: bank initiates annual report detailing investigations http://web.worldbank.org/WBSITE/EXTERNAL/NEWS/0,,contentMDK:20368613~menuPK:34463~pagePK:64003015~piPK:64003012~theSitePK:4607,00.html webcite
  • [2]A New global partnership: eradicate poverty and transform economies through sustainable development http://www.un.org/sg/management/pdf/HLP_P2015_Report.pdf webcite
  • [3]Fighting corruption in the health sector: methods, tools and good practices http://www.undp.org.tt/News/UNODC/Anticorruption%20Methods%20and%20Tools%20in%20Health%20Lo%20Res%20final.pdf webcite
  • [4]Mackey TK, Liang BA: Combating healthcare corruption and fraud with improved global health governance. BMC Int Health Hum Rights 2012, 12:23. BioMed Central Full Text
  • [5]Mackey TK, Liang BA: Off label promotion reform: a legislative proposal for addressing vulnerable patient drug access and limiting inappropriate pharmaceutical marketing. Univ Michigan J Law Reform 2011, 45:1.
  • [6]Johnson & Johnson reaches .2 billion Risperdal settlement http://digitaljournal.com/article/361538#ixzz2mXVb7ztJ webcite
  • [7]What is good governance? http://www.unescap.org/pdd/prs/ProjectActivities/Ongoing/gg/governance.asp webcite
  • [8]Helping countries combat corruption: the role of the World Bank http://www1.worldbank.org/publicsector/anticorrupt/corruptn/cor02.htm#note1 webcite
  • [9]Corruption and the provision of health care and education services http://www.imf.org/external/pubs/ft/wp/2000/wp00116.pdf webcite
  • [10]Jaén M, Paravisini D, et al.: Wages, capture, and penalties in Venezuela’s public hospitals. In Diagnosis Corruption: Fraud in Latin America’s Public Hospitals. Edited by Di Tella R, Savedoff W. Washington DC: Latin American Research Network, Inter-American Development Bank; 2001.
  • [11]Di Tella R, Savedoff W: Shining light in dark corners. In Diagnosis Corruption: Fraud in Latin America’s Public Hospitals. Edited by Di Tella R, Savedoff W. Washington DC: Latin American Research Network, Inter-American Development Bank; 2001.
  • [12]Ferrinho P, Van Lerberghe W: Managing health professionals in the context of limited resources: a fine line between corruption and the need for moonlighting. Washington, DC: World Bank Publications; 2002.
  • [13]Pregnant women in Burkina Faso dying because of discrimination http://www.amnesty.org/en/news-and-updates/report/pregnant-women-burkina-faso-dying-because-discrimination-20100127 webcite
  • [14]Mackey TK, Liang BA: Rebalancing brain drain: exploring resource reallocation to address health worker migration and promote global health. Health Policy 2012, 107:1.
  • [15]The anti-corruption catalyst: realising the MDGs by 2015 http://www.transparency-usa.org/documents/AntiCorruptionCatalystRealisingtheMDGby2015.pdf webcite
  • [16]Schargrodsky E, Mera J, Weinschelbaum F: Transparency and accountability in Argentina’s hospitals. In Diagnosis Corruption: Fraud in Latin America’s Public Hospitals. Edited by Di Tella R, Savedoff W. Washington DC: Latin American Research Network, Inter-American Development Bank; 2001.
  • [17]Mackey TK, Liang BA: A United Nations global health panel for global health governance. Soc Sci Med 2012, 76:1.
  • [18]Mackey TK, Liang BA: The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci 2011, 100:4571-4579.
  • [19]Cohen JC, Mrazek M, Hawkins L: Tackling corruption in the pharmaceutical systems worldwide with courage and conviction. Clin Pharmacol Ther 2007, 81:445-449.
  • [20]The global use of medicines: outlook through 2016 http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf webcite
  • [21]Kohler JC, Ovtcharenko N: Good governance for medicines initiatives: exploring lessons learned. U4 Anti-Corrupt Resour Centre 2013, 3:1-26.
  • [22]Cohen J, Montoya J: Using technology to fight corruption in pharmaceutical purchasing: lessons from the Chilean experience. World Bank Institute 2001.
  • [23]Fiscal year 2008 annual integrity report: protecting Development’s potential http://siteresources.worldbank.org/INTDOII/Resources/INT_AnnualReport_web.pdf webcite
  • [24]WHO Good Governance for Medicines programme: an innovative approach to prevent corruption in the pharmaceutical sector http://www.who.int/healthsystems/topics/financing/healthreport/25GGM.pdf webcite
  • [25]Medicines transparency alliance: implementing our pilot phase http://www.medicinestransparency.org/uploads/media/MeTA_Implementing-pilot-phase_01.pdf webcite
  • [26]The global fund to fight AIDS, tuberculosis and malaria annual report 2002/2003 http://www.theglobalfund.org/en/library/publications/annualreports/ webcite
  • [27]Breakthrough on procurement to save $140 million http://www.theglobalfund.org/en/mediacenter/newsreleases/2013-11-05_Breakthrough_on_Procurement_to_Save_USD_140_Million/ webcite
  • [28]The global fund strategy 2012-2016: investing for impact http://www.theglobalfund.org/en/about/strategy/ webcite
  文献评价指标  
  下载次数:9次 浏览次数:49次